As shown in Supplementary Table 1, patients with type 2 diabetes had a median disease duration of 9.5 years and were primarily treated with metformin (87.5%) and SGLT2 inhibitors (62.5%). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.